These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 25284038)

  • 41. Galectin-3 Overrides PTRF/Cavin-1 Reduction of PC3 Prostate Cancer Cell Migration.
    Meng F; Joshi B; Nabi IR
    PLoS One; 2015; 10(5):e0126056. PubMed ID: 25942420
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of the interaction between galectin-3 and cell adhesion molecules in cancer metastasis.
    Xin M; Dong XW; Guo XL
    Biomed Pharmacother; 2015 Feb; 69():179-85. PubMed ID: 25661355
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cytosolic galectin-7 impairs p53 functions and induces chemoresistance in breast cancer cells.
    Grosset AA; Labrie M; Gagné D; Vladoiu MC; Gaboury L; Doucet N; St-Pierre Y
    BMC Cancer; 2014 Nov; 14():801. PubMed ID: 25367122
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Galectin inhibitors and nanoparticles as a novel therapeutic strategy for glioblastoma multiforme.
    Elliott W; Tsung AJ; Guda MR; Velpula KK
    Am J Cancer Res; 2024; 14(2):774-795. PubMed ID: 38455415
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mesenchymal ovarian cancer cells promote CD8
    Yakubovich E; Cook DP; Rodriguez GM; Vanderhyden BC
    NPJ Syst Biol Appl; 2023 Dec; 9(1):61. PubMed ID: 38086828
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel fusion protein PK5-RL-Gal-3C inhibits hepatocellular carcinoma via anti-angiogenesis and cytotoxicity.
    Gao X; Jiang P; Wei X; Zhang W; Zheng J; Sun S; Yao H; Liu X; Zhang Q
    BMC Cancer; 2023 Feb; 23(1):154. PubMed ID: 36793021
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting galectin-driven regulatory circuits in cancer and fibrosis.
    Mariño KV; Cagnoni AJ; Croci DO; Rabinovich GA
    Nat Rev Drug Discov; 2023 Apr; 22(4):295-316. PubMed ID: 36759557
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of galectins in cancer: Biological challenges for their clinical application.
    Laderach DJ; Compagno D
    Front Immunol; 2022; 13():1104625. PubMed ID: 36703969
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Galectin-3 in prostate cancer and heart diseases: a biomarker for these two frightening pathologies?
    Lima T; Perpétuo L; Henrique R; Fardilha M; Leite-Moreira A; Bastos J; Vitorino R
    Mol Biol Rep; 2023 Mar; 50(3):2763-2778. PubMed ID: 36583779
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting disordered-structured domain interactions in Galectin-3 based on NMR and enhanced MD.
    Bhattacharya S; Zhang M; Hu W; Qi T; Heisterkamp N
    Biophys J; 2022 Nov; 121(22):4342-4357. PubMed ID: 36209362
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcoma.
    Herrador-Cañete G; Zalacain M; Labiano S; Laspidea V; Puigdelloses M; Marrodan L; Garcia-Moure M; Gonzalez-Huarriz M; Marco-Sanz J; Ausejo-Mauleon I; de la Nava D; Hernández-Osuna R; Martínez-García J; Silva-Pilipich N; Gurucega E; Patiño-García A; Hernández-Alcoceba R; Smerdou C; Alonso MM
    Mol Ther Oncolytics; 2022 Sep; 26():246-264. PubMed ID: 35949950
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of galectins‑1, 3, 7, 8 and 9 as potential diagnostic and therapeutic markers in ovarian cancer (Review).
    Mielczarek-Palacz A; Kondera-Anasz Z; Smycz-Kubańska M; Englisz A; Janusz A; Królewska-Daszczyńska P; Wendlocha D
    Mol Med Rep; 2022 May; 25(5):. PubMed ID: 35293602
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    Timári I; Balla S; Fehér K; Kövér KE; Szilágyi L
    Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057096
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Unraveling How Tumor-Derived Galectins Contribute to Anti-Cancer Immunity Failure.
    Laderach DJ; Compagno D
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572756
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Galectin‑3 blockade suppresses the growth of cetuximab‑resistant human oral squamous cell carcinoma.
    Yin P; Cui S; Liao X; Yao X
    Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34328195
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Galectin-3 promotes noncanonical inflammasome activation through intracellular binding to lipopolysaccharide glycans.
    Lo TH; Chen HL; Yao CI; Weng IC; Li CS; Huang CC; Chen NJ; Lin CH; Liu FT
    Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301890
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An Integrated Meta-Analysis of Secretome and Proteome Identify Potential Biomarkers of Pancreatic Ductal Adenocarcinoma.
    de Oliveira G; Freire PP; Cury SS; de Moraes D; Oliveira JS; Dal-Pai-Silva M; Reis PP; Carvalho RF
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32197468
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Understanding and Targeting Apoptotic Pathways in Ovarian Cancer.
    Al-Alem LF; Baker AT; Pandya UM; Eisenhauer EL; Rueda BR
    Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31652965
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pectasol-C Modified Citrus Pectin targets Galectin-3-induced STAT3 activation and synergize paclitaxel cytotoxic effect on ovarian cancer spheroids.
    Hossein G; Halvaei S; Heidarian Y; Dehghani-Ghobadi Z; Hassani M; Hosseini H; Naderi N; Sheikh Hassani S
    Cancer Med; 2019 Aug; 8(9):4315-4329. PubMed ID: 31197964
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Role of Galectins in Tumor Progression, Treatment and Prognosis of Gynecological Cancers.
    Chetry M; Thapa S; Hu X; Song Y; Zhang J; Zhu H; Zhu X
    J Cancer; 2018; 9(24):4742-4755. PubMed ID: 30588260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.